25 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2031. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Apr 2031
Next term end
15
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2036 · High confidence
Also notable
Ends Nov 2032 · High confidence
Also notable
Ends Aug 2034 · High confidence
Also notable
Ends Jan 2032 · High confidence
Also notable
Ends no later than Jun 2034 · Low confidence
Also notable
Ends May 2037 · High confidence
Also notable
Ends Oct 2035 · High confidence
Also notable
Ends Oct 2034 · High confidence
Multi-Functional Hemocompatible Porous Polymer Bead Sorbent for Removing Protein Based Toxins and Potassium from Biological Fluids
US 11,040,061
Cited by 23 later US patents, top 10% of utility patents granted in 2021 in our data. Protection runs to 2036.
Method of Treating Inflammation
US 9,717,755
Cited by 26 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Hemocompatibility Modifiers for Cross-Linked Polymeric Material
US 11,752,250
Cited by 3 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2034.
Polymeric Sorbent for Removal of Impurities From Whole Blood and Blood Products
US 10,064,406
The most cited patent in this portfolio, cited by 34 later US patents, top 10% of utility patents granted in 2018 in our data. Protection runs to 2032.
Methods for Reducing Contamination in a Biological Substance
US 11,602,585
Granted 2023. Computed term ends 2034. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Use of a Hemocompatible Porous Polymer Bead Sorbent for Removal of Endotoxemia-Inducing Molecules
US 11,065,600
Granted 2021. Computed term ends 2037.
Use Of Gastrointestinally Administered Porous Enteron Sorbent Polymers To Prevent Or Treat Radiation Induced Mucositis, Esophagitis, Enteritis, Colitis, And Gastrointestinal Acute Radiation Syndrome
US 10,314,859
Granted 2019. Computed term ends 2035. A terminal disclaimer caps this term to an earlier patent's.
Polymeric Sorbent for Removal of Impurities from Whole Blood and Blood Products
US 10,426,158
Granted 2019. Computed term ends 2034.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 11, 2026The maintenance fee for Use Of Gastrointestinally Administered Porous Enteron Sorbent Polymers To Prevent Or Treat Radiation Induced Mucositis, Esophagitis, Enteritis, Colitis, And Gastrointestinal Acute Radiation Syndrome (US 10,314,859) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
- 1 fee due Feb 15, 2027The maintenance fee for Multi-Functional Hemocompatible Porous Polymer Bead Sorbent For Removing Protein Based Toxins And Potassium From Biological Fluids (US 11,723,916) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
- 1 fee due Mar 12, 2027The maintenance fee for Hemocompatibility Modifiers for Cross-Linked Polymeric Material (US 11,752,250) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
- 1 fee due Apr 1, 2027The maintenance fee for Polymeric Sorbent for Removal of Impurities from Whole Blood and Blood Products (US 10,426,158) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Use Of A Hemocompatible Porous Polymer Bead Sorbent For Removal Of Endotoxemia-Inducing Molecules (US 11,826,724) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Connector Assembly and Methods of Use (US 11,969,535) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- 3 terms have ended since Aug 23, 2026
- Nov 20 US 9,604,196 Size-Selective Hemocompatible Polymer System · term ended
- Nov 20 US 8,211,310 Size-Selective Polymer System · term ended
- Nov 20 US 7,875,182 Size-Selective Hemoperfusion Polymeric Adsorbents · term ended
What they patent
The largest of its 15 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,034,894 | Method of Treating Inflammation In force · High confidence | In force | High confidence | |
| US 10,946,040 | Method of Treating Inflammation In force · Medium confidence | In force | Medium confidence | |
| US 10,967,001 | Method of Treating Inflammation In force · Medium confidence | In force | Medium confidence | |
| US 11,058,715 | Method of Treating Inflammation In force · High confidence | In force | High confidence | |
| US 10,064,406 | Polymeric Sorbent for Removal of Impurities From Whole Blood and Blood Products In force · High confidence | In force | High confidence | |
| US 9,717,755 | Method of Treating Inflammation In force · High confidence | In force | High confidence | |
| US 12,280,196 | Methods of Using Polymers In force · Low confidence | In force | Low confidence | |
| US 11,020,521 | Hemocompatibility Modifiers for Cross-Linked Polymeric Material In force · High confidence | In force | High confidence | |
| US 11,602,585 | Methods for Reducing Contamination in a Biological Substance In force · Low confidence | In force | Low confidence | |
| US 11,752,250 | Hemocompatibility Modifiers for Cross-Linked Polymeric Material In force · High confidence | In force | High confidence |
Also on record, not counted in the 25: 14 patents ended · 3 applications pending · 12 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.